<unk>  is used for its anxiolytic effect, and as an adjunctive therapy in epilepsy. As an adjunctive therapy in epilepsy, it is used in patients who have not responded to first-line drugs and in children who are refractory to first-line drugs. It is unclear if there are any benefits to<unk>  over other seizure medications for children with Rolandic epilepsy or other epileptic syndromes. It is not recommended for use in children between the ages of six months and three years, unless there is a compelling need. In addition to epilepsy and severe anxiety,<unk>  is also approved as a short-term (2–4 weeks) adjunctive agent in schizophrenia and other psychotic disorders to manage anxiety or agitation.<unk>  is sometimes used for refractory epilepsies. However, long-term prophylactic treatment of epilepsy may have considerable drawbacks, most importantly decreased antiepileptic effects due to drug tolerance which may render long-term therapy less effective. Other antiepileptic drugs may therefore be preferred for the long-term management of epilepsy. Furthermore, benzodiazepines may have the drawback, particularly after long-term use, of causing rebound seizures upon abrupt or over-rapid discontinuation of therapy forming part of the benzodiazepine withdrawal syndrome.<unk>  is approved in Canada for add-on use in tonic-clonic, complex partial, and myoclonic seizures.<unk>  is approved for adjunctive therapy in complex partial seizures, certain types of status epilepticus, specifically the mycolonic, myoclonic-absent, simple partial, complex partial, and tonic varieties, and non-status absence seizures. It is also approved for the treatment of anxiety. In India,<unk>  is approved for use as an adjunctive therapy in epilepsy, and in acute and chronic anxiety. In Japan,<unk>  is approved for adjunctive therapy in treatment-resistant epilepsy featuring complex partial seizures. In New Zealand,<unk>  is marketed as Frisium In the United Kingdom<unk>  (Frisium) is approved for short-term (2–4 weeks) relief of acute anxiety in patients who have not responded to other drugs, with or without insomnia and without uncontrolled clinical depression. It was not approved in the United States until October 25, 2011, when it was approved for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients 2 years of age or older.
Clobazam
Ketazolam
Midazolam
Mexazolam
Remimazolam
Adinazolam
Triazolam
Flutazolam